新型的伊米达佐[4,5-c]化物化合物作为TLR7激动剂治疗癌症
1Smith Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
ACS medicinal chemistry letters
|February 19, 2025
概括
新型的伊米达佐[4,5-c]皮里丁化合物被呈现为托尔类受体7 (TLR7) 抑制剂. 这些化合物显示出对癌症治疗的潜力,并提供了新的制备方法.
科学领域:
- 药用化学 医学化学
- 免疫学 免疫学 免疫学
- 有机合成 有机合成
背景情况:
- 收费类受体7 (TLR7) 是一个关键的免疫受体,参与病原体识别和自身免疫性疾病.
- 向TLR7提供了一个有希望的策略,用于调节癌症治疗中的免疫反应.
相关概念视频
Tumor Immunotherapy
463
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
110
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
110


